Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3

Active, not recruiting

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: TAK-788
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2019-10-16

Last Posted Date: 2024-11-28

Lead Sponsor: Takeda

Target Recruit Count: 354

Registration Number: NCT04129502

Locations: 🇮🇹
AORN Dei Colli- Ospedale Monaldi Napoli, Napoli, Campania, Italy
🇺🇦
Private Enterprise Private Manufacturing Company Acinus, Kropyvnytskyi, Ukraine
🇨🇳
Icahn School of Medicine at Mount Sinai, Beijing, China

and more 129 locations

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Malignant Solid Tumor
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Biological: GEN1042
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-FU
Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2019-09-10

Last Posted Date: 2024-12-03

Lead Sponsor: Genmab

Target Recruit Count: 1287

Registration Number: NCT04083599

Locations: 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸
Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸
Moores Cancer Center at the UC San Diego Health, San Diego, California, United States

and more 72 locations

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Lazertinib
Drug: Amivantamab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2019-09-04

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 701

Registration Number: NCT04077463

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
UCSF Helen Diller Comprehensive, San Francisco, California, United States

and more 75 locations

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Procedure: Therapeutic Conventional Surgery
Drug: Pemetrexed
Drug: Pemetrexed Disodium

First Posted Date: 2019-08-20

Last Posted Date: 2022-03-04

Lead Sponsor: University of California, San Francisco

Registration Number: NCT04061590

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: KN046
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2019-08-13

Last Posted Date: 2019-09-10

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 50

Registration Number: NCT04054531

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced and Metastatic Solid Tumors

Interventions: Drug: Ociperlimab
Drug: Tislelizumab
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Drug: 5fluorouracil
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2019-08-07

Last Posted Date: 2024-11-29

Lead Sponsor: BeiGene

Target Recruit Count: 449

Registration Number: NCT04047862

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇦🇺
St Vincents Hospital, Fitzroy, Victoria, Australia
🇨🇳
Beijing Tongren Hospital, Cmu, Beijing, Beijing, China

and more 26 locations

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Nivolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Placebo
Drug: Pemetrexed
Drug: Docetaxel

First Posted Date: 2019-07-19

Last Posted Date: 2024-07-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 461

Registration Number: NCT04025879

Locations: 🇺🇸
Local Institution - 0086, Traverse City, Michigan, United States
🇺🇸
Local Institution - 0103, Fredericksburg, Virginia, United States
🇨🇦
Local Institution - 0062, Oshawa, Ontario, Canada

and more 102 locations

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Phase 1

Terminated

Conditions: Small-cell Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: ALRN-6924
Drug: Carboplatin
Drug: Topotecan
Drug: Placebo
Drug: Pemetrexed

First Posted Date: 2019-07-17

Last Posted Date: 2022-10-10

Lead Sponsor: Aileron Therapeutics, Inc.

Target Recruit Count: 35

Registration Number: NCT04022876

Locations: 🇺🇸
Mount Sinai Cancer Research Program, Miami, Florida, United States
🇺🇸
Regional Medical Oncolgy Center, Wilson, North Carolina, United States
🇺🇸
Gabrail Cancer Institute, Canton, Ohio, United States

and more 25 locations